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INTRODUCTION

Transcranial magnetic stimulation (TMS) is a noninvasive technique for cortical
stimulation that uses electromagnetic induction to generate a strong fluctuating magnetic field which induces intracranial currents 1 . Single pulse (spTMS) and paired-pulse TMS (ppTMS) studies have been shown to be safe and effective in studying a variety of measures of motor cortex excitability including resting motor threshold, motor evoked potential amplitude, recruitment curves, cortical silent period, short interval intracortical inhibition, long interval intracortical inhibition and intracranial facilitation 2 . It is now a state of the art technique for studying neurophysiology in vivo. Repetitive TMS (rTMS) applies repeated TMS pulses at set frequencies or bursts of stimulation to induce changes in cortical excitability which last longer than the period of stimulus administration by minutes to hours with more durable changes in clinical outcomes reported when rTMS is given in daily sessions for 1-6 weeks 3 . These alterations have generally been observed as a decrease in cortical excitability with low-frequency stimulation (≤ 1 Hz) and an increase in cortical excitability with high frequency rTMS (≥ 5 Hz) 3 . rTMS demonstrates therapeutic potential for many conditions in adults including depression 4 , eating disorders 5 , epilepsy 6 , schizophrenia 7 , tinnitus 8, 9 , migraine 10 , and Parkinson's Disease 9 11 .
In children, possible therapeutic benefits have been reported for motor function and tics 12, 13 14 15 . Theta-burst stimulation (TBS) is a newer form of rTMS that administers 50 Hz bursts of 3 pulses every 200 msec either continuously (cTBS) or in intermittent 2-second trains every 10 seconds (iTBS) 16 . TBS may induce longer lasting cortical inhibition (cTBS) or excitation (iTBS) than standard rTMS 16 . In general, benefits when present have been of small to moderate magnitude and short-lived. Still, given the potential for M A N U S C R I P T
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clinical benefit and limitations of medical options there is a need for further studies of rTMS/TBS as a therapeutic intervention 4, 8 .
The use of TMS in both healthy and clinical adult populations has been associated with several adverse events of varying severity. The most common are transient headaches and scalp discomfort, which are thought to be due to activation of scalp pericranial muscles 17, 18 . However, more severe adverse effects may include mood changes, and induction of seizures 17 . Seizures during TMS are thought to be a result of cortical pyramidal cell activation, spread of excitation to neighboring neurons, and persistent changes in motor cortical inhibition 19 . Whether TMS can induce seizures is theoretically possible but controversial given the extremely rare occurrence. We wanted to provide a brief but complete review of all published studies where TMS have been used in children, and describe adverse events, in order to provide a safety profile of TMS in children for researchers and clinicians as well as safety measures for IRBs. This is of crucial importance regarding the increasing number of published studies using these tools on pediatric populations ( Figure 1 ).
METHODS
We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for the conduct and reporting of this review. The different phases of this systematic review are displayed in the PRISMA flowchart ( Figure 2 ).
Literature Review
An extensive literature search for English language studies on TMS use in children was M A N U S C R I P T
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conducted through PubMed and links from publications from 1/1/1985 through 10/31/2016. Review articles were excluded except when presenting novel data. The searches used included the following key words: transcranial magnetic stimulation, TMS, TBS, Children, Child, Pediatric. Dealing with missing data: while our searches were comprehensive, there is a possibility that we may have missed relevant studies, however we believe this to be unlikely. We sought missing data from study authors; yet, many failed to respond. We intended to present all studies in the main report (Table 1 ). All applicable articles were reviewed for patient demographics (gender, age, and patient phenotype), TMS protocol used (TMS modality and stimuli intensity) and adverse events reported.
Grading adverse events
Adverse events were graded in accordance with the Common Terminology Criteria for Adverse Events (CTCAE v4.0) 20 . This commonly accepted grading scale divides adverse events into five different categories (Grade 1-5) depending on their severity. Only Grades 1-3 are present in this report. Grade 1 is a mild event that needs no intervention, Grade 2 is a moderate event with noninvasive intervention needed, and Grade 3 is a severe event,
but not life-threatening, that calls for hospitalization.
Statistical Analysis
We extracted all adverse events reported in each TMS and/or TBS study. We computed the proportion estimate of crude risk per session, population, and modality. We also M A N U S C R I P T
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separated single pulse/paired pulse, rTMS and TBS studies and tested for group differences. Risks were calculated as per-session risk. Confidence intervals were calculated utilizing the Clopper-Pearson method in SPSS software version 23, and group differences were calculated via multivariate ANOVA with WLS weighting per session.
RESULTS
Studies including single and paired-pulse TMS
We identified 42 studies utilizing single or paired pulse techniques in child patients .
This included 639 healthy children, 482 children with central nervous system (CNS) disorders, and separately 84 epileptic children. Of these studies, 10 reported adverse events (Table 2 43 , and neurocardiogenic syncope (n=2) 21 .
Studies including repetitive TMS
We identified 23 rTMS studies involving child patients 13-15, 21, 64-82 including a total of 230 children with CNS disorders and 76 children with Epilepsy. There were 81 adverse events that were attributed to rTMS protocols in the CNS disorder population ( Table 2 ).
The mild adverse events were as follows: headache (n=45) 15 0.0003 -0.0041).
Studies including theta-burst stimulation
We identified three theta-burst studies involving 90 healthy children and 40 children with CNS disorders 43, 62, 79 . Of these studies, two identified adverse events ( arm/other pain (n=1) 43 . that are lacking in similar recent reviews. In two cases, patients were diagnosed and treated for depression with sertraline which has been associated with seizures, albeit rarely 85, 86 . In the first case, prolonged hypomania was also reported. Hypomania is the worst grade level for adverse events in this review. While this is a unique case, hypomania is more likely a side-effect of selective serotonin reuptake inhibitor-type antidepressants such as sertraline 87 . In the second case 65 , atypical antipsychotic olanzapine was also taken by the patient on a daily basis. While antipsychotics decrease seizure threshold to varying degrees, olanzapine is known to be safer than other atypical antipsychotics considering side effects 88 . Still, isolated cases of olanzapine-induced clinical seizure have been reported 89, 90 . With multiple seizure risk factors, it is of crucial importance that TMS investigators carefully screen for medications and other potential seizure precipitants. The most recent case was an unmedicated youth with major depressive disorder treated with deep TMS 68 . Deep TMS uses H-coils that induce an effective field at a wider depth l compared to standard figure-8 TMS coils 91 . Generalized seizures in adults, as well as typical mild adverse events, have been reported during deep TMS simulation similarly as figure-8 coil stimulation 92 . However, deep TMS technology is new and continuous surveillance is needed due to its particular mode of action.
Comparing Populations and Modalities
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In regards to other moderate adverse events, the two cases of neurocardiogenic syncope were associated with pre-existing circumstances that would induce syncope. Of the two children, one failed to intake any food prior to the application and had a prior history of syncope with venipuncture, and the other had a history of early-morning presyncope with micturition and anxiety attacks 21, 93 . Noted as the most common adverse event related
with either TMS or TBS in our literature search, mild transient headaches have been shown to be a relatively frequent side-effect of TMS and are easily quelled with acetaminophen or nonsteroidal anti-inflammatory medications 94 . Finally, local discomfort as well as neck or arm stiffness/pain, tingling, nausea/dizziness, anxiety and discomfort are also common transient mild side-effect of TMS 95 .
We report one study in epileptic children where TMS induced an increase in seizure frequency up to 3 days after TMS in four children based on a phone questionnaire In this review, we demonstrated that both children and adults seem to experience similar adverse events during TMS experiments. Nonetheless, because neuronal networks M A N U S C R I P T
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are the targets of the resulting electrical currents induced during the transcranial magnetic stimulation, the effects on a developing brain should be monitored carefully; the safety of TMS in child populations may thus be contemplated independently of the safety considerations in adult populations. A good example is the MEP threshold, directly related to the degree of myelination of the corticospinal tracts (i.e. the less myelinated the tracts, the higher the threshold), which decreases with age 97 . So, with higher motor thresholds, rTMS trials on children may be conducted at much higher output power than in adults. Adult safety guidelines on the maximum intensity may then not be appropriate for children. We suggest safety measures for children to be established through brain measures of activation and connectivity at different exposure levels (i. 17 . This included statements that indeed were revised such as "Children should not be used as subjects for rTMS without compelling clinical reasons, such as the treatment of refractory epilepsy or depression". There is an urgent need of criteria and guidelines applicable to children with or without epilepsy, neurological disorders and other medical conditions, as well as a systematic reporting system of AEs occurring in TMS laboratories. In this systematic review, we focused on accuracy and hope that biases from all the aforementioned issues did not deviate our main findings. In addition, we hope that this review combined with the most recent ones will help establishing appropriate guidelines for the use of TMS in children.
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CONCLUSION
Over the past 30 years, over 4000 children with or without neuropsychiatric diseases have 2) ; Dark Gray -Sever AEs (or Grade 3). * Number of adolescent participants is exact, whereas number of adverse events is from the entire population of the study (n=36).
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